Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 6/20 | 0.53 |
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP14 | P50281 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900500 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4034426 | 0.84 | HRH4 (0.56) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL23099845 | 0.83 | ATAD2 (0.47) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4039329 | 0.79 | ATAD2 (0.49) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30052471 | 0.79 | HRH4 (0.59) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL4407862 | 0.79 | HRH4 (0.59) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL3707866 | 0.78 | RAB9A (0.61) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30568660 | 0.78 | HSD17B10 (0.54) | KDM4EALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL18322257 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL30489216 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747220-B1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMA INC (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | AVENTIS PHARMACEUTICALS INC. (US) | 2008-08-21 | — | — | US | claimed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | claimed |
| WO-2024182382-A1 | 4,5-FUSED BICYCLIC PYRROLIDINE AND 4,5-FUSED BICYCLIC PYRROLIDINONE COMPOUNDS | CYTEIR THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024118524-A1 | AZAINDOLE COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | CEREVEL THERAPEUTICS, LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-4306166-A2 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Aquinnah Pharmaceuticals Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-1747220-A1 | SUBSTITUTED 1H-PYRROLO 3,2-B, 3,2-C, AND 2,3-C¨PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | Aventis Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1636224-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | Prosidion Limited (GB) | 2006-03-22 | — | — | EP | disclosed |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PROSIDION LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| WO-2005061498-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B, 3,2-C, AND 2,3-C]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | US | disclosed |
| WO-2004104001-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDE INHIBITORS OF GLYCOGEN PHOSHORYLASE | PROSIDION LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
| WO-1994029307-A1 | PYRROLO[3,2-B]PYRIDINYLALKYL BENZAMIDE DERIVATIVES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5360907-A | Platelet activating factor | G.D. SEARLE & CO. (US) | 1994-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | KDM4E 4150/4885ALDH1A1 3706/4885RAB9A 704/4885 |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | KDM4E 2030/4885ALDH1A1 3407/4885RAB9A 2689/4885 |
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885ALDH1A1 972/4885RAB9A 1378/4885 |
| US-20080200496-A1 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie | CSNK1E, CSNK1G3, CSNK2A3 | KDM4E 141/4885ALDH1A1 3613/4885RAB9A 3253/4885 |
| US-20050131012-A1 | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | CSNK2A3, PACSIN2, CSNK1G3 | KDM4E 502/4885ALDH1A1 4044/4885RAB9A 4131/4885 |
| US-20050261272-A1 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase | PYGL, PYGM, PYGB | KDM4E 2422/4885ALDH1A1 720/4885RAB9A 4373/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | KDM4E 732/4885ALDH1A1 2021/4885RAB9A 2531/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KDM4E 732/4885ALDH1A1 2021/4885RAB9A 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.